MedPath

Safety and Efficacy Study of a Food Supplement for Pregnant and Lactating Women

Not Applicable
Withdrawn
Conditions
Anaemia
Interventions
Dietary Supplement: Food supplement
Registration Number
NCT02190565
Lead Sponsor
Oriflame Cosmetics AB
Brief Summary

The purpose of this study is to determine whether a food supplement consisting of vitamins, minerals and fish oil taken during and after pregnancy can decrease the need for additional iron supplementation due to anemia during pregnancy, and optimize levels of nutritional markers such as vitamin D and docosahexaenoic acid (DHA, an omega 3 fatty acid) in maternal blood and breast milk, compared to placebo.

Detailed Description

200 healthy, pregnant women will be randomized to receive either active or placebo at their first visit to the pre-natal centres. They will be monitored at regular intervals, blood samples will be taken and they will be asked about compliance and any adverse reactions.

Approx 8 weeks after delivery, the women will come to the pre-natal centres for a check-up. During this visit, a blood sample will be drawn and a breast milk sample will be collected.

The blood samples will be analysed for haemoglobin, serum ferritin, vitamin D and DHA. The breast milk samples will be analysed for vitamin D and DHA.

Recruitment & Eligibility

Status
WITHDRAWN
Sex
Female
Target Recruitment
Not specified
Inclusion Criteria
  • Healthy pregnant women aged 18-40 years with a body mass index (BMI) above 18.5 and below 35 kg/m2 who visit pre-natal clinics (midwife centres) to register.
  • Nulliparous and multiparous women.
  • The women must be able to understand verbal and written information in Swedish to give an informed consent to participate in the study.
Exclusion Criteria
  • Women below the age of 18 or above 40 years old.
  • Women with a BMI below 18.5 or above 35 kg/m2.
  • Women with any form of anaemia as diagnosed at the first visit to the prenatal clinic.
  • Women expecting two or more babies.
  • Women who have undergone bariatric surgery.
  • Women on medication with pharmaceuticals that could affect the result of the study, e.g., vitamin K antagonists.
  • Women who are allergic to any of the components of WellnessPack mama, e.g., fish.
  • Women who suffer from drug or alcohol abuse.
  • Women who suffer from known severe eating disorders.
  • Women who suffer from chronic diseases that could affect gastrointestinal absorption and metabolism.
  • Women who want to continue or start using similar food supplements in addition to WellnessPack mama/placebo, unless recommended by a physician or midwife, will be excluded from the study.
  • Upon miscarriage or transfer to prenatal care specialist, the subject is excluded from the study.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Food supplementFood supplementFood supplement consisting of fish oil (omega 3 fatty acids DHA and EPA) and multivitamin and mineral tablets with extra iron and folic acid
PlaceboFood supplementPlacebo consisting of two sham multivitamin and mineral tablets and two capsules of oil
Primary Outcome Measures
NameTimeMethod
Prevalence of anaemia in active and placebo groupspregnancy week 28-30

Blood will be analysed for haemoglobin and ferritin values. We will compare how many women in each group (active vs placebo) are ordinated iron supplementation due to anaemia by mid-pregnancy.

Secondary Outcome Measures
NameTimeMethod
Levels of nutritional biomarkers in maternal blood and breast milk6-10 weeks after delivery

Levels of nutritional biomarkers such as DHA and vitamin D in maternal blood and breast milk will be measured in active and placebo groups.

Trial Locations

Locations (1)

Department of Woman and Child Health, Division of Obstetrics and Gynecology, Karolinska Institutet

πŸ‡ΈπŸ‡ͺ

Stockholm, Sweden

Β© Copyright 2025. All Rights Reserved by MedPath